Contrast‑enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early‑phase non‑small cell lung cancer

Abstract

Abstract. Non-small cell lung cancer (NSCLC) is a major cause of morbidity and mortality, and patients with NSCLC are frequently diagnosed at an advanced stage. This is primarily due to a lack of advanced and sensitive protocols for the detection of early stage NSCLC. Therefore, methods for the accurate diagnosis of early stage NSCLC are urgently required to improve survival rates. The present study investigated the use of contrast-enhanced computerized tomography (CECT) combined with a targeted nanoparticle contrast agent (TNCA) to diagnose early-stage NSCLC in a mice xenograft model. The TNCA used was lenvatinib, a multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, proto-oncogene tyrosine-protein kinase receptor Ret and mast/stem cell growth factor receptor Kit. Xenograft NSCLC mice were established and used to analyze the efficacy of CECT-TNCA compared with CT scanning alone. The TNCA was inhaled with the use of an atomizer. The results demonstrated that CECT-TNCA improved the sensitivity of the diagnosis of early stage NSCLC. In addition, imaging using the TNCA enabled the visualization of nodules in the lung in mice with early stage NSCLC. In addition, lung nodule signal enhancement was increased in CECT-TNCA compared with CT, suggesting a high accurate accumulation of the TNCA in tumor nodules. Mice diagnosed with early stage NSCLC exhibited a higher eradication rate of NSCLC after treatment with cisplatin compared with mice with advanced stage NSCLC. These data indicate that the sensitivity and accuracy of CT imaging for the diagnosis of early stage NSCLC was improved through combination with the liposome-encapsulated TNCA.

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

“…Taken together, the data obtained in the present study indicates that GdCho-Len is a stable and safe nanoparticle contrast agent for diagnosing patients with lung cancer. Contrast agent may increase the sensitivity and accuracy of CT imaging for the diagnosis of early stage NSCLC (23). A novel nano-sized chistosan/Fe 3 O 4 -enclosed bispecific antibody had been identified as an efficient contrast agent in lung cancer diagnosis (40).…”

“…It has been reported that developing multimodal contrast agent would enhance the diagnostic accuracy of PET/CT, as well as increase the diagnostic accuracy sensitivity in patients with lung cancer (23). A previous study reported that contrast-enhanced ultrasound with a novel nanoparticle contrast agent increases the diagnostic efficacy in patients with NSCLC (24).…”

Anti-cancer binary system activated by bacteriophage HK022 integrase

“…Moreover, the systemic delivery of the binary system by retro-orbital injections caused irreversible changes in the injection region that might have reduced the delivery efficiency, especially in the later steps. Better diagnostic tests that discover earlier stages of the lung cancer such as luc bioluminescence imaging [ 60 ], small-molecular fluorescent probes [ 61 ] or contrast-enhanced computerized tomography [ 62 ] for earlier DNA deliveries may lead to an improved or complete survival. Moreover, a combination of the binary system with different anti-cancer approaches may enhance the longevity of the treated cancer mice.…”

Lepidic growth component as a favorable prognostic factor in non–small cell lung cancer of ≤3 cm

“…The development of imaging technology, such as computed tomography (CT), has increased the identification and surgical treatment of small‐sized non–small cell lung cancer (NSCLC) in recent years. 1 Previous studies have reported that small‐sized NSCLC with ground‐glass opacity (GGO) is non‐invasive with little vessel invasion or lymph node metastasis and has an improved prognosis compared to tumors without GGO 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ; this is because the GGO component is usually pathologically equivalent to a lepidic growth component (LGC). 2 , 12 , 13 , 14 , 15 Therefore, some researchers have suggested that the stage of NSCLC can be determined by the GGO component.…”